Mpox, once a rare virus mainly confined to parts of Central Africa, is rapidly evolving into a more serious global health ...

Common symptoms of mpox are a skin rash or mucosal lesions, which can last two to four weeks, accompanied by fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.

“Tecovirimat did not lead to vast resolution of mpox skin lesions and did not improve pain control in those with clade II mpox,” Timothy Wilkin, MD, MPH, chief of the division of infectious ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails ...

Sierra Leone on Wednesday started injecting frontline health care workers and high-risk individuals and children from age 12 ...

The NIH is running another trial called STOMP in the US in people with lab-confirmed or suspected mpox infections, also focusing on time to clinical resolution of skin lesions. Meanwhile ...

Mpox, caused by a virus from the same family as smallpox, can be transmitted between humans through close physical contact. It causes fever, muscular aches and large boil-like skin lesions ...

Common symptoms of mpox are a skin rash or mucosal lesions, which can last two to four weeks, accompanied by fever, headache, muscle aches, back pain, low energy and swollen lymph nodes. “Mpox can be ...

The model focuses on orthopoxviruses - which includes the viruses that cause smallpox and mpox. The researchers recently published a study on their work using the model in the journal ...

The MVA-BN vaccine showed an overall effectiveness of 57.8% (95% CI, 11.8-83.0) in reducing mpox cases at 14 days or longer after the first dose; however, the effectiveness was lower in people ...

In the next stage, the research team plans to conduct long-term studies and investigate the effects of a third vaccine dose. Reference: Hillus D, Le NH, Tober-Lau P, et al. Safety and effectiveness of ...